Abstract
Genotype of apolipoprotein E has been identified in a group of randomly selected Polish subjects participating in a cross-sectional study performed within the POL-MONICA Program, the part of international study WHO-MONICA Project. The investigated group consisted of 170 persons, 92 males and 78 females aged 41–69 years (mean age 62.0 ± 5.11). The observed frequency of apolipoprotein E alleles was: ε2 – 7.6%, ε3 – 81.8% and ε4 – 10.6%, which was similar to frequencies in the neighbouring European countries. Statistically significant lower means of total cholesterol (TC) and of low density lipoprotein cholesterol (LDL-C) levels in ε2 carriers and higher means of TC, of LDL-C and of triglycerides in ε4 carriers were observed as compared with noncarriers of respective alleles. Some nonlipid cardiovascular risk factors (hypertension (HT) and obesity) and coronary heart disease (CHD) showed a tendency to lower prevalence in the ε2 allele carriers as compared to noncarriers. In the ε4 allele carriers a tendency to higher prevalence of HT, but not of CHD was observed as compared to noncarriers of this allele.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1–21.
Wilson PWF, Schafer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. Arteriosclerosis Thromb Vasc Biol 1996; 16: 1250–1255.
Frikke-Schmidt R, Tybjaerg-Hansen A, Steffensen R, Jensen G, Nordestgaard BG. Apolipoprotein E genotype: Epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease. J Am Coll Cardiol 2000; 35: 1192–1199.
Lahoz C, Schaefer EJ, Cupples LA et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001; 154: 529–537.
WHO MONICA Project (prepared by Wolf H, Tuomilehto J, Kuulasmaa K et al.). Blood pressure levels in the 41 populations of the WHO Monica Project. J Hum Hypertens 1997; 11: 733–742.
WHO MONICA Project (prepared by Chambless L, Keil U, Dobson A et al.). Population versus clinical view of case fatality from acute coronary heart disease: Results from the WHO MONICA Project 1985–1990. Circulation 1997; 96: 3849–3859.
Pająk A, Williams OD, Broda G et al. Changes over time in blood lipids and their correlates in polish rural and urban populations: The correlates of fibrinogen and factor VII activity in Polishurban and rural populations. Int J Epidemiol 1998; 27: 953–961.
Rywik S, Davis CE, Pająk A et al. Poland and US Collaborative Study on Cardiovascular Epidemiology Hypertension in the Community: Prevalence, Awareness, Treatment and Control of Hypertension in the Pol-MONICA Project and the US Atherosclerosis Risk in Communities Study. Ann Epidemiol 1998; 8: 3–13.
Sans S., Kesteloot H., Kromhout D. The burden of cardiovascular diseases mortality in Europe. Eur Heart J 1997; 18: 1231–1248.
Rywik S, Sznajd J, Kulesza W, et al. Sikora D. Monitoring of trends and determinants of cardiovascular disease. ‘Pol-MONICA’ Part II. Material and methods (in Polish). Przeg Lek 1985; 2: 256–266.
WHO MONICA Manual, December 1989, CVD/ MNC Geneva, WHO, 1989.
Rose GA, Blackburn H, Gillium FF, Prineas RJ. Cardiovascular survey methods. WHO, Geneva, 1982; 123.
Prineas JR, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings. John Wright PSG Inc., Boston, Bristol, London, 1982.
Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545–548.
Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds.), The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, Inc., 1995; 1953–1980.
Kowalska A, Wiechmann I, Walter H. Genetic variability of apolipoprotein E in a polishpopulation. Hum Biol 1998; 70: 1093–1099.
Weisgraber KH, Innerarity TL, Mahley RW. Abnormal receptor binding activity of the human E apoprotein due to cysteine–arginine interchange at a single site. J Biol Chem 1982; 257: 2518–2581.
Bohnet K, Pillot T, Visvikis S, Sabolovic N, Siest G. Apolipoprotein (apo) E genotype and apo E concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J Lipid Res 1996; 37: 1316–1324.
Bioletto S, Fontana P, Darioli R, James RW. Apolipoprotein E polymorphism and the distribution profile of very low density lipoproteins; an influence of the E4 allele on large (Sf >60) particles. Atherosclerosis 1998; 138: 207–215.
Kesaniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 1987; 80: 578–581.
Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apo e phenotype: A meta-analysis. J Lipid Res 1992; 33: 447–454.
Wang XL, McCredie RM, Wilcken DEL. Polymorphism of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arteriosclerosis Thromb Vasc Biol 1995; 15: 1030–1034.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bednarska-Makaruk, M., Broda, G., Kurjata, P. et al. Apolipoprotein E genotype, lipid levels and coronary heart disease in a Polish population group. Eur J Epidemiol 17, 789–792 (2001). https://doi.org/10.1023/A:1015657709060
Issue Date:
DOI: https://doi.org/10.1023/A:1015657709060